Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 | 2014-03-31 | 2013-03-31 | 2012-03-31 | 2011-03-31 | 2010-03-31 | 2009-03-31 | 2008-03-31 | 2007-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | INR 332.8B | INR 353.5B | INR 325.5B | INR 279.2B | INR 245.9B | INR 214.4B | INR 2.6B | INR 174.6B | INR 153.9B | INR 142.0B | INR 140.8B | INR 154.7B | INR 148.2B | INR 132.2B | INR 116.3B | INR 96.7B | INR 74.7B | INR 70.3B | INR 69.4B | INR 50.0B | INR 65.2B |
| Bruttoergebnis | INR 166.9B | INR 186.5B | INR 190.4B | INR 163.6B | INR 139.3B | INR 113.8B | INR 1.3B | INR 94.0B | INR 83.4B | INR 76.3B | INR 78.4B | INR 92.3B | INR 85.4B | INR 75.8B | INR 60.6B | INR 53.3B | INR 40.3B | INR 36.3B | INR 36.5B | INR 25.4B | INR 30.9B |
| Bruttomarge % | 50.1% | 52.8% | 58.5% | 58.6% | 56.7% | 53.1% | 50.8% | 53.8% | 54.2% | 53.7% | 55.6% | 59.7% | 57.6% | 57.4% | 52.1% | 55.1% | 53.9% | 51.7% | 52.6% | 50.8% | 47.4% |
| Betriebsergebnis (EBIT) | INR 35.2B | INR 48.9B | INR 71.8B | INR 67.7B | INR 57.1B | INR 29.5B | INR 431M | INR 16.0B | INR 20.9B | INR 11.9B | INR 13.5B | INR 29.6B | INR 26.3B | INR 26.0B | INR 21.1B | INR 18.3B | INR 12.6B | INR 2.0B | (INR 2.8B) | INR 3.4B | INR 11.3B |
| Operative Marge % | 10.6% | 13.8% | 22.1% | 24.3% | 23.2% | 13.8% | 16.9% | 9.2% | 13.6% | 8.4% | 9.6% | 19.1% | 17.7% | 19.7% | 18.2% | 18.9% | 16.9% | 2.9% | -4.1% | 6.7% | 17.2% |
| Jahresüberschuss | INR 33.2B | INR 45.1B | INR 56.5B | INR 55.7B | INR 45.1B | INR 23.6B | INR 232M | INR 19.5B | INR 18.8B | INR 9.8B | INR 12.0B | INR 20.0B | INR 22.2B | INR 21.5B | INR 16.8B | INR 14.3B | INR 11.0B | INR 1.1B | (INR 5.2B) | INR 4.7B | INR 9.3B |
| Nettomarge % | 10.0% | 12.8% | 17.4% | 20.0% | 18.3% | 11.0% | 9.1% | 11.2% | 12.2% | 6.9% | 8.6% | 12.9% | 15.0% | 16.3% | 14.4% | 14.7% | 14.8% | 1.5% | -7.4% | 9.4% | 14.3% |
| EBITDA | INR 55.6B | INR 83.3B | INR 96.7B | INR 88.4B | INR 74.4B | INR 45.1B | INR 535M | INR 41.8B | INR 35.5B | INR 23.6B | INR 24.8B | INR 39.9B | INR 34.4B | INR 33.1B | INR 22.5B | INR 20.3B | INR 16.8B | INR 6.6B | INR 1.5B | INR 7.3B | INR 14.3B |
| Ergebnis je Aktie (EPS) | INR 39.81 | INR 54.11 | INR 67.77 | INR 66.80 | INR 54.17 | INR 28.34 | INR 0.28 | INR 23.48 | INR 22.62 | INR 11.80 | INR 14.42 | INR 23.40 | INR 25.95 | INR 25.21 | INR 19.69 | INR 16.76 | INR 12.99 | INR 1.26 | INR -6.14 | INR 5.55 | INR 11.74 |
| Ausstehende Aktien (Mio.) | 833M | 833M | 834M | 834M | 832M | 832M | 832M | 830M | 831M | 831M | 835M | 855M | 855M | 853M | 852M | 851M | 850M | 848M | 842M | 843M | 796M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für RDY. /companies/us/RDY
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms